Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterocolitis, Pseudomembranous | 6 | 2016 | 91 | 1.990 |
Why?
|
| Diarrhea | 7 | 2023 | 301 | 1.460 |
Why?
|
| Norovirus | 6 | 2015 | 287 | 1.390 |
Why?
|
| Caliciviridae Infections | 5 | 2015 | 286 | 1.180 |
Why?
|
| Gastroenteritis | 5 | 2011 | 308 | 1.110 |
Why?
|
| Travel | 4 | 2010 | 117 | 0.870 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2023 | 215 | 0.790 |
Why?
|
| Immunocompromised Host | 2 | 2015 | 315 | 0.630 |
Why?
|
| Cross Infection | 4 | 2014 | 339 | 0.540 |
Why?
|
| Histoplasmosis | 2 | 2008 | 55 | 0.510 |
Why?
|
| Antifungal Agents | 4 | 2015 | 292 | 0.500 |
Why?
|
| Spores, Bacterial | 1 | 2016 | 23 | 0.470 |
Why?
|
| Echinocandins | 2 | 2015 | 42 | 0.460 |
Why?
|
| Organ Transplantation | 2 | 2015 | 175 | 0.460 |
Why?
|
| Candidemia | 1 | 2015 | 43 | 0.430 |
Why?
|
| Secondary Prevention | 1 | 2016 | 217 | 0.420 |
Why?
|
| Rifamycins | 3 | 2010 | 18 | 0.390 |
Why?
|
| Food Microbiology | 2 | 2009 | 24 | 0.350 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 526 | 0.350 |
Why?
|
| Anti-Infective Agents | 3 | 2016 | 266 | 0.350 |
Why?
|
| Enterobacteriaceae | 2 | 2009 | 40 | 0.350 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2012 | 71 | 0.340 |
Why?
|
| Histoplasma | 2 | 2008 | 37 | 0.330 |
Why?
|
| Itraconazole | 2 | 2008 | 24 | 0.330 |
Why?
|
| Dysentery | 1 | 2010 | 5 | 0.310 |
Why?
|
| Restaurants | 2 | 2009 | 13 | 0.300 |
Why?
|
| Antidiarrheals | 1 | 2009 | 17 | 0.290 |
Why?
|
| Benzoxazines | 1 | 2007 | 23 | 0.260 |
Why?
|
| Colitis | 1 | 2009 | 166 | 0.260 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 311 | 0.250 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 3061 | 0.250 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2015 | 1280 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 4 | 2014 | 2596 | 0.250 |
Why?
|
| Soft Tissue Infections | 1 | 2008 | 90 | 0.250 |
Why?
|
| Bacterial Infections | 1 | 2010 | 327 | 0.240 |
Why?
|
| Vegetables | 1 | 2008 | 267 | 0.240 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 218 | 0.230 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 328 | 0.230 |
Why?
|
| Clostridium Infections | 3 | 2014 | 250 | 0.220 |
Why?
|
| Humans | 31 | 2023 | 131163 | 0.210 |
Why?
|
| Hospitals, University | 3 | 2014 | 103 | 0.200 |
Why?
|
| Crohn Disease | 2 | 2017 | 292 | 0.200 |
Why?
|
| Age of Onset | 2 | 2017 | 592 | 0.200 |
Why?
|
| Feces | 4 | 2015 | 721 | 0.180 |
Why?
|
| Serotonin | 1 | 2023 | 208 | 0.180 |
Why?
|
| Male | 19 | 2017 | 64957 | 0.180 |
Why?
|
| Constipation | 1 | 2023 | 131 | 0.180 |
Why?
|
| Adult | 16 | 2022 | 31282 | 0.170 |
Why?
|
| Community-Acquired Infections | 2 | 2014 | 254 | 0.170 |
Why?
|
| Texas | 5 | 2015 | 3686 | 0.170 |
Why?
|
| Heart Transplantation | 1 | 2008 | 800 | 0.170 |
Why?
|
| Mexico | 3 | 2010 | 190 | 0.160 |
Why?
|
| Risk Factors | 5 | 2015 | 11074 | 0.160 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2014 | 401 | 0.150 |
Why?
|
| Neoplasms | 1 | 2014 | 3016 | 0.150 |
Why?
|
| Female | 16 | 2017 | 70963 | 0.140 |
Why?
|
| Graft Rejection | 2 | 2015 | 552 | 0.130 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 1882 | 0.130 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 732 | 0.130 |
Why?
|
| Sigmoid Diseases | 1 | 2016 | 7 | 0.120 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2016 | 6 | 0.120 |
Why?
|
| Anus Diseases | 1 | 2016 | 15 | 0.120 |
Why?
|
| Ulcer | 1 | 2016 | 52 | 0.120 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2016 | 38 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 5196 | 0.110 |
Why?
|
| Probiotics | 2 | 2010 | 227 | 0.110 |
Why?
|
| Endoscopy, Digestive System | 1 | 2016 | 155 | 0.110 |
Why?
|
| Prevalence | 3 | 2012 | 2701 | 0.110 |
Why?
|
| Rifampin | 1 | 2016 | 128 | 0.110 |
Why?
|
| Middle Aged | 11 | 2017 | 28601 | 0.110 |
Why?
|
| Hospitals, Community | 1 | 2015 | 51 | 0.110 |
Why?
|
| Gram-Positive Bacteria | 1 | 2014 | 44 | 0.110 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2014 | 44 | 0.110 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2014 | 52 | 0.110 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2014 | 71 | 0.100 |
Why?
|
| Stomach | 1 | 2016 | 274 | 0.100 |
Why?
|
| Gastrostomy | 1 | 2014 | 85 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2016 | 6459 | 0.100 |
Why?
|
| Thiazoles | 2 | 2011 | 113 | 0.100 |
Why?
|
| Candidiasis, Invasive | 1 | 2014 | 24 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2016 | 319 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2016 | 238 | 0.100 |
Why?
|
| Aged | 9 | 2016 | 21025 | 0.100 |
Why?
|
| Young Adult | 5 | 2017 | 10103 | 0.100 |
Why?
|
| Precancerous Conditions | 1 | 2016 | 281 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 321 | 0.100 |
Why?
|
| Transplant Recipients | 1 | 2015 | 235 | 0.100 |
Why?
|
| Graft Survival | 1 | 2015 | 465 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2015 | 497 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 4066 | 0.090 |
Why?
|
| Treatment Outcome | 5 | 2016 | 12936 | 0.090 |
Why?
|
| Malnutrition | 1 | 2014 | 163 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2014 | 396 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 992 | 0.090 |
Why?
|
| Creatinine | 1 | 2013 | 398 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2017 | 5063 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 2904 | 0.080 |
Why?
|
| Colon | 1 | 2014 | 373 | 0.080 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 18 | 0.080 |
Why?
|
| Child | 4 | 2015 | 26341 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 259 | 0.080 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2014 | 327 | 0.080 |
Why?
|
| Guatemala | 1 | 2010 | 63 | 0.080 |
Why?
|
| Adolescent | 6 | 2017 | 20987 | 0.080 |
Why?
|
| Immunization, Passive | 1 | 2010 | 120 | 0.080 |
Why?
|
| Geography | 1 | 2010 | 114 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2016 | 550 | 0.080 |
Why?
|
| India | 1 | 2010 | 234 | 0.070 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 808 | 0.070 |
Why?
|
| Prognosis | 2 | 2017 | 4886 | 0.070 |
Why?
|
| Hospitalization | 2 | 2015 | 1950 | 0.070 |
Why?
|
| Infection Control | 1 | 2010 | 158 | 0.070 |
Why?
|
| Food Handling | 1 | 2008 | 14 | 0.070 |
Why?
|
| Enterotoxins | 1 | 2008 | 77 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 1267 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2008 | 137 | 0.070 |
Why?
|
| Virulence | 1 | 2008 | 268 | 0.070 |
Why?
|
| Mycophenolic Acid | 1 | 2008 | 54 | 0.070 |
Why?
|
| Amphotericin B | 1 | 2008 | 89 | 0.070 |
Why?
|
| Antigens, Fungal | 1 | 2007 | 32 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 423 | 0.060 |
Why?
|
| Debridement | 1 | 2008 | 95 | 0.060 |
Why?
|
| Alkynes | 1 | 2007 | 27 | 0.060 |
Why?
|
| Thoracic Wall | 1 | 2008 | 40 | 0.060 |
Why?
|
| Tacrolimus | 1 | 2008 | 100 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 903 | 0.060 |
Why?
|
| Cyclopropanes | 1 | 2007 | 70 | 0.060 |
Why?
|
| Republic of Korea | 2 | 2017 | 50 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2007 | 237 | 0.060 |
Why?
|
| Salicylates | 1 | 2006 | 54 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1618 | 0.060 |
Why?
|
| Developing Countries | 1 | 2008 | 305 | 0.060 |
Why?
|
| Bismuth | 1 | 2006 | 84 | 0.060 |
Why?
|
| Organometallic Compounds | 1 | 2006 | 110 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 1129 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2006 | 141 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 614 | 0.050 |
Why?
|
| Time Factors | 2 | 2017 | 6196 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1173 | 0.050 |
Why?
|
| Biopsy | 1 | 2008 | 1239 | 0.050 |
Why?
|
| Anti-HIV Agents | 1 | 2007 | 345 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 663 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2010 | 1559 | 0.050 |
Why?
|
| Control Groups | 1 | 2003 | 11 | 0.050 |
Why?
|
| Behavioral Research | 1 | 2003 | 17 | 0.050 |
Why?
|
| Diet, Gluten-Free | 1 | 2022 | 4 | 0.050 |
Why?
|
| Monosaccharides | 1 | 2022 | 21 | 0.050 |
Why?
|
| Sucrose | 1 | 2022 | 35 | 0.050 |
Why?
|
| Starch | 1 | 2022 | 26 | 0.050 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2022 | 28 | 0.050 |
Why?
|
| Risk | 2 | 2014 | 726 | 0.050 |
Why?
|
| Fermentation | 1 | 2022 | 67 | 0.050 |
Why?
|
| Oligosaccharides | 1 | 2022 | 71 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2014 | 15110 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 2085 | 0.040 |
Why?
|
| Nitro Compounds | 2 | 2011 | 22 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2010 | 3711 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2065 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3436 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 6797 | 0.040 |
Why?
|
| Infant | 1 | 2014 | 13352 | 0.040 |
Why?
|
| Azathioprine | 1 | 2017 | 35 | 0.030 |
Why?
|
| Adalimumab | 1 | 2017 | 22 | 0.030 |
Why?
|
| Mercaptopurine | 1 | 2017 | 72 | 0.030 |
Why?
|
| Infliximab | 1 | 2017 | 61 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2017 | 84 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 294 | 0.030 |
Why?
|
| Acetic Acid | 1 | 2016 | 17 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2016 | 43 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 144 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 311 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1121 | 0.030 |
Why?
|
| Metaplasia | 1 | 2016 | 215 | 0.030 |
Why?
|
| Metronidazole | 1 | 2016 | 161 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2003 | 910 | 0.030 |
Why?
|
| Nanospheres | 1 | 2014 | 6 | 0.030 |
Why?
|
| Enterococcus | 1 | 2014 | 30 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2014 | 118 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 101 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 613 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 98 | 0.030 |
Why?
|
| Blood | 1 | 2014 | 98 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2016 | 243 | 0.030 |
Why?
|
| United States | 1 | 2009 | 12072 | 0.020 |
Why?
|
| Candida | 1 | 2014 | 79 | 0.020 |
Why?
|
| Intestines | 1 | 2017 | 587 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 166 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2014 | 286 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 129 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2016 | 17753 | 0.020 |
Why?
|
| Serum | 1 | 2013 | 41 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2014 | 298 | 0.020 |
Why?
|
| Vancomycin | 1 | 2014 | 226 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1356 | 0.020 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 235 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 539 | 0.020 |
Why?
|
| Logistic Models | 1 | 2016 | 1797 | 0.020 |
Why?
|
| Bacteremia | 1 | 2014 | 446 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2010 | 80 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2010 | 45 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2825 | 0.020 |
Why?
|
| Ice Cream | 1 | 2009 | 2 | 0.020 |
Why?
|
| Animals | 1 | 2010 | 33912 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1205 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 1717 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 3360 | 0.020 |
Why?
|
| Cytokines | 1 | 2014 | 1339 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 789 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 859 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 694 | 0.010 |
Why?
|
| Biomarkers | 1 | 2014 | 3385 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2009 | 991 | 0.010 |
Why?
|